Skip to main content

Table 3 Clinical and laboratory parameters in ARF group and non-ARF group

From: The incidence, risk factors, and clinical outcomes of rhabdomyolysis associated with fenoverine prescription: a retrospective study in South Korea (1999–2014)

Clinical and laboratory parametersARF group (n = 7)Non-ARF group (n = 15)P
Age58.3 ± 10.558.1 ± 9.60.962
Sex  0.671
 Male (%)5 (71.4)9 (60) 
 Female (%)2 (28.6)6 (40) 
Drug duration (days)15.9 ± 7.813.0 ± 9.40.494
Drug total dose (mg)4757.1 ± 2345.83753.3 ± 2723.90.412
WBC (× 103/uL)9.4 ± 5.45.9 ± 2.00.034
CK (U/L)26,467.8 ± 22,434.318,601.6 ± 11,893.80.290
LDH (U/L)2836.0 ± 2497.62080.1 ± 712.30.282
AST (U/L)1495.8 ± 718.3967.3 ± 553.90.085
ALT (U/L)464.9 ± 215.7350.8 ± 240.80.327
Albumin (g/dL)3.2 ± 0.62.7 ± 0.60.105
BUN (mg/dL)56.7 ± 32.317.3 ± 6.9< 0.001
Creatinine (mg/dL)4.2 ± 2.60.8 ± 0.3< 0.001
Sodium (mmol/L)131.1 ± 6.5137.8 ± 5.50.020
Potassium (mmol/L)5.2 ± 0.84.3 ± 0.40.001
Hospital days17.6 ± 9.822.9 ± 9.40.234
Clinical signs and symptoms
 Muscle pain (%)7 (100)13 (86.7)0.545
 Muscle weakness (%)3 (42.9)6 (40.0)1.000
 Oliguria (%)4 (57.1)0 (0)0.005
 Dark urine (%)2 (28.6)1 (6.7)0.227
LC (%)5 (26.3)14 (93.3)0.227
Child-Pugh classification  0.312
 A (%)0 (0)3 (21.4) 
 B (%)1 (20.0)6 (42.9) 
 C (%)4 (80.0)5 (35.7) 
Severe hepatic derangement4 (80)5 (35.7)0.376
Etiology of LC  0.830
 Hepatitis B (%)3 (60)9 (64.3) 
 Hepatitis C (%)1 (20)1 (5.3) 
 Alcohol (%)1 (20)3 (25.1) 
 Cryptogenic (%)0 (0)1 (5.3) 
Death (%)4 (57.1)0 (0)0.005
  1. WBC White Blood Cell, CK Creatine Kinase, LDH Lactate Dehydrogenase, AST Aspartate Transaminase, ALT Alaninine Transminase, BUN Blood Urea Nitrogen, DM Diabetes Mellitus, ARF Acute Renal Failure, LC Liver Cirrhosis